Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the protocol is to estimate the complete response rate of three courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell lymphoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Treatments: Ifosfamide; Mitoxantrone; Prednisone; Rituximab; Vinblastine; Vinorelbine

Criteria

Inclusion Criteria:

• Both genders, between 18 and 75 years old

• CD 20+ large cell lymphoma

• In first relapse

• No previous autologous stem cell transplantation or relapsing more than 12 months after an autologous stem cell transplantation

• Ann Arbor stage I, II, III ou IV

• ECOG 0,1 or 2

• Signed informed consent

Exclusion Criteria:

• age: before 18 and more than 75 years old

• other type of lymphoma

• Informed consent not signed